SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 35,234 shares of the company's stock, valued at approximately $1,710,000. SG Americas Securities LLC owned approximately 0.07% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMPH. YHB Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at $27,000. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter worth about $55,000. Blue Trust Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock valued at $70,000 after purchasing an additional 309 shares in the last quarter. nVerses Capital LLC grew its position in shares of Amphastar Pharmaceuticals by 37.5% in the second quarter. nVerses Capital LLC now owns 2,200 shares of the company's stock valued at $88,000 after purchasing an additional 600 shares during the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth approximately $93,000. Institutional investors and hedge funds own 65.09% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on AMPH shares. StockNews.com upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, September 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $63.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Richard K. Prins sold 17,101 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company's stock, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Rong Zhou sold 4,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,383 shares of company stock valued at $1,524,123 in the last ninety days. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.1 %

Shares of AMPH stock traded up $0.04 during mid-day trading on Wednesday, reaching $46.32. The company's stock had a trading volume of 297,777 shares, compared to its average volume of 402,104. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $2.27 billion, a PE ratio of 16.03, a price-to-earnings-growth ratio of 0.92 and a beta of 0.83. The company's 50 day simple moving average is $46.19 and its 200-day simple moving average is $42.90. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. On average, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.